Rawad A Yared, Chieh-Chang Chen, Astrid Vandorpe, Marianna Arvanitakis, Myriam Delhaye, Michael Fernandez Y Viesca, Vincent Huberty, Daniel Blero, Emmanuel Toussaint, Axel Hittelet, Didier Verset, Walter Margos, Olivier Le Moine, Hassane Njimi, Wei-Chih Liao, Jacques Devière, Arnaud Lemmers
OBJECTIVE: Hemin, a heme oxygenase 1 activator has shown efficacy in the prevention and treatment of acute pancreatitis in mouse models. We conducted a randomized controlled trial (RCT) to assess the protective effect of Hemin administration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in patients at risk. METHODS: In this multicenter, multinational, placebo-controlled, double-blind RCT, we assigned patients at risk for PEP to receive a single intravenous dose of Hemin (4 mg/kg) or placebo immediately after ERCP...
February 15, 2024: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]